EMLA CREAM 2.5 %
PRILOCAINE : 2.5 % LIDOCAINE : 2.5 % · DIN 00886858 · ASPEN PHARMACARE CANADA INC.
Health Canada status: MARKETED
What is EMLA CREAM?
EMLA CREAM 2.5 % contains PRILOCAINE : 2.5 % LIDOCAINE : 2.5 %. It is listed in the Health Canada Drug Product Database under DIN 00886858, held by ASPEN PHARMACARE CANADA INC., supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 01-Jun-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EMLA CREAM used for?
EMLA Cream (lidocaine 2.5% and prilocaine 2.5%) is indicated for topical analgesia of intact skin in connection with needle insertion, vaccination with specific vaccines (MMR, DPTP; Haemophilus influenzae b and Hepatitis B), superficial surgical procedures, and laser treatment for superficial skin surgeries. It is also indicated for topical analgesia of genital mucosa in connection with local infiltration anesthesia and surgical procedures lasting not longer than 10 minutes on small superficial localized lesions, and for topical analgesia of leg ulcers in connection with mechanical/sharp cleansing/debridement. EMLA Patch (lidocaine 2.5% and prilocaine 2.5%) is indicated for use in topical analgesia of intact skin in connection with needle insertion and vaccination with specific vaccines (MMR, DPTP; Haemophilus influenzae b and Hepatitis B).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00886858 |
|---|---|
| Brand name | EMLA CREAM |
| Generic / active ingredient | PRILOCAINE : 2.5 % LIDOCAINE : 2.5 % |
| Manufacturer | ASPEN PHARMACARE CANADA INC. |
| Strength | 2.5 % |
| Dosage form | CREAM |
| Route of administration | TOPICAL |
| Schedule | Ethical |
| ATC code | N01BB54 PRILOCAINE, COMBINATIONS |
| AHFS class | 72:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Jun-2018 |
| Original market date | 1991-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
EMLA Cream is available in 5 g aluminium tubes with occlusive dressings and 30 g aluminium tubes without dressings. EMLA Patch is available in boxes of 2 or 20 single-use transdermal patches per box.
What can be used instead?
Other Canadian products sharing ATC code N01BB54 PRILOCAINE, COMBINATIONS. 4 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 | 0.005 MG | SOLUTION | DENTSPLY CANADA LIMITED | MARKETED | DIN 02347695 |
| EMLA PATCH | 2.5 % | PATCH | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02057794 |
| PRILOCAINE HCL 4% EPINEPH 1:200000INJ | 40 MG | SOLUTION | NOVOCOL PHARMACEUTICAL OF CANADA INC | MARKETED | DIN 00393746 |
| DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 | 5 MCG | SOLUTION | DENTSPLY CANADA LIMITED | CANCELLED POST MARKET | DIN 00519227 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.